1. Home
  2. DLB vs BLLN Comparison

DLB vs BLLN Comparison

Compare DLB & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$66.06

Market Cap

5.5B

Sector

Miscellaneous

ML Signal

HOLD

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$97.06

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLB
BLLN
Founded
1965
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical Specialities
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2004
2025

Fundamental Metrics

Financial Performance
Metric
DLB
BLLN
Price
$66.06
$97.06
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$90.75
$126.71
AVG Volume (30 Days)
893.4K
801.1K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.28%
N/A
EPS Growth
N/A
103.40
EPS
1.84
0.48
Revenue
N/A
$305,112,000.00
Revenue This Year
$6.22
$46.29
Revenue Next Year
$3.84
$30.14
P/E Ratio
$35.47
$197.98
Revenue Growth
N/A
99.97
52 Week Low
$48.26
$61.96
52 Week High
$74.62
$150.44

Technical Indicators

Market Signals
Indicator
DLB
BLLN
Relative Strength Index (RSI) 78.42 41.41
Support Level $62.42 $81.73
Resistance Level $66.68 $97.36
Average True Range (ATR) 1.31 5.88
MACD 0.32 -1.35
Stochastic Oscillator 97.44 14.85

Price Performance

Historical Comparison
DLB
BLLN

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: